April 12th 2024
Data showed that 87.8% of treated patients and 96.1% of patients who completed the study achieved normal 24-hour mean plasma testosterone values (222 to 800 ng/dL) at 90-day follow-up.
September 28th 2023
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Prostate cancer treatment type strongest predictor of complications
February 24th 2014The type of primary treatment received for prostate cancer-surgery or radiation therapy-is the strongest predictor of lesser-known complications such as the need for additional surgical procedures and development of secondary cancers, according to the authors of a recently published study from the University of Toronto.
Anti-androgen shows benefit in pre-chemo setting
February 21st 2014The second-generation androgen receptor antagonist enzalutamide (XTANDI) significantly improved survival and delayed the time to chemotherapy in men with previously untreated metastatic castrate-resistant prostate cancer, according to a recent study.
How to talk to patients about prostate cancer screening
February 11th 2014In this article, I outline my patient discussion concerning prostate cancer screening, which includes defining what the PSA test is, why to screen or not to screen, the screening controversy, current guidelines, and decision aids.
ADT affects men’s mental, emotional well-being
February 10th 2014Prostate cancer patients treated with androgen deprivation therapy experienced changes in mental and emotional well-being during treatment, although there was no meaningful decline in emotional quality of life 2 years after treatment, a recent study found.
Test predicts prostate cancer radiation therapy failure
February 3rd 2014A genomic test capable of predicting the probability of developing metastatic prostate cancer outperformed existing clinical risk factors for predicting biochemical failure and distant metastasis following radiation therapy, researchers reported at the Genitourinary Cancers Symposium in San Francisco.
Prostate cancer tests guide treatment, identify aggressive disease
January 31st 2014Separate studies at the Genitourinary Cancers Symposium highlighted the utility of prostate cancer tests Prolaris and ConfirmMDx for Prostate Cancer for treatment planning and identifying aggressive disease, respectively.
Anti-androgen’s benefit in chemo-naïve men tops prostate cancer news
January 31st 2014The androgen-receptor blocker enzalutamide (XTANDI) increases survival by 29% in men with metastatic castration-resistant prostate cancer (mCRPC) and delays progression of the disease by 81%, according to new phase III study results in men who had not previously received chemotherapy.
ICSI outcomes similar with fresh, frozen sperm
January 22nd 2014In men with nonobstructive azoospermia, frozen and fresh testicular sperm offer similar fertilization and pregnancy rates, according to the authors of a meta-analysis who say it is the first such study to specifically address the fresh-versus-frozen debate in this population.
Study may explain exercise, prostate cancer outcome link
January 20th 2014Men who walked at a fast pace prior to prostate cancer diagnosis had more regularly shaped blood vessels in their prostate tumors compared with men who walked slowly, providing a potential explanation for why exercise is linked to improved outcomes for men with prostate cancer.
Surgery type has no effect on high-risk prostate cancer outcomes
January 20th 2014Type of surgical approach-open or robot assisted-appears to have no effect on specific clinical outcomes in patients undergoing radical prostatectomy for high-risk prostate cancer, nor does the procedure influence the pathway subsequent therapy might follow, according to a recent study.
Protocol may eliminate need for opioids after robot-assisted laparoscopic prostatectomy
January 20th 2014More than 85% of patients undergoing robot-assisted laparoscopic prostatectomy may not require opioid analgesia either immediately post-op, in hospital, or upon release, according to a recent study.
Missed follow-up leads to stage IV renal cancer, death
January 14th 2014A lawsuit was filed against both the urologist and the radiologist involved in the treatment of the kidney stone, claiming that he was not informed of the abnormality on the left kidney noted on the CT scan and the recommendation for follow-up.
Metastatic prostate cancer deaths unchanged over past 25 years
January 6th 2014PSA screening has likely played an important role in the 40%-plus drop in prostate cancer mortality since the late 1980s, although the mortality rate for metastatic disease has remained the same, say study authors from the University of California, Davis.